# Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

> **NCT01012973** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 177 (actual)

## Conditions studied

- Retinal Vein Occlusion

## Interventions

- **BIOLOGICAL:** Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
- **OTHER:** Sham treatment

## Key facts

- **NCT ID:** NCT01012973
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2011-02
- **Final completion:** 2012-02
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2014-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01012973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01012973, "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01012973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*